Method for Production of L-Valin by Fermentation Using Coryneform Bacteria Having Switched-Off Amino Transferase Activity

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention describes a method for producing L-amino acids, especially L-valine, using Coryneform bacteria (like Corynebacterium glutamicum) in which the activity of the enzyme alanine transaminase is reduced or completely switched off. By genetically modifying bacteria to knock out or diminish the function of this enzyme, the production of unwanted by-products (such as alanine) is minimized, leading to a higher yield of the target amino acid (L-valine). The patent also covers the genetic sequences, vectors, and recombinant strains involved in this process.

Use CasesContent extracted from patent full text and abstract with AI.

• Industrial-scale production of L-valine for dietary supplements, animal feed, and pharmaceuticals.
• Biotechnological manufacturing of other amino acids (like L-isoleucine or L-lysine) from pyruvate using optimized bacterial strains.
• Production of L-amino acids with minimal by-product (alanine) contamination for food and feed industries.
• Development of genetically engineered bacterial strains for specialized fermentation processes.

BenefitsContent extracted from patent full text and abstract with AI.

• Increases the yield of L-valine and related amino acids by reducing by-product (alanine) formation.
• Enables more efficient and cost-effective industrial fermentation processes.
• Reduces purification steps, resulting in lower production costs and higher purity products.
• Provides a platform for further genetic optimization of amino acid-producing microbes.
• Applicable to a variety of carbon sources (like glucose, sucrose, starch), enhancing process flexibility.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

Microbial production of L-amino acids (I) in which (a) alanine transaminase (AT) activity or (b) alanine production is reduced or switched off, is new. Independent claims are included for: (1) nucleic acid sequence (NA) containing nucleotides (nt) 101-1414 of a 1414 nt DNA sequence (1); (2) gene structure (GS) containing NA, i.e. the alanine transaminase gene; (3) vector containing GS or NA; (4) chromosome containing GS or NA; (5) recombinant cell containing GS, the vector of (3), chromosome of (4) or NA; (6) plasmid containing internal sequences of the AT gene or the sequences adjacent to the 3' and 5'-ends of this gene; and (7) alanine transaminase having a 437 amino acid sequence (2), reproduced.